Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 29

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 29
---
 ​ | ​ | ​ | ​                    | ​ | 149,996 | ​ | ​ | ​ | ​                     | ​ | 150,009 | ​ | ​ | ​ | ​                        | ​ | ― | ​ | ​ | ​ | ​        | ​ | 365,005 | ​ | ​ |

(1) Represents the grant date fair value of stock option and RSU awards granted in 2024 computed in accordance with stock- based accounting rules (Financial Standards Accounting Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Stock Compensation ). For information regarding assumptions underlying the valuation of equity awards, see Note 13 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. Our directors will only realize compensation to the extent that: (i) the fair value of our common stock is greater than the exercise price of such stock options and/or (ii) any of their RSUs vest. The option and RSU grants referenced above vest as to 100% of the option shares on the first anniversary of the grant date, provided that the director remains in continuous service with the Company through the vesting date. (2) Effective January 28, 2025, Paul Hastings and Andreas Wicki resigned from our board. (3) Effective June 30, 2024, Gary Pace retired from our board. The fees paid in cash represent a proration based on the time he served on the board during 2024. In conjunction with Dr. Pace’s retirement, we and Dr. Pace entered into a fifth amendment to the consulting agreement, dated June 2, 2011, by and between Pacira Pharmaceuticals, Inc., our operating subsidiary, and Dr. Pace, effective June 12, 2024, that has a one-year term from July 1, 2024 through and including June 30, 2025 for consideration of $3,200 per calendar quarter for up to eight hours of consulting work. As of December 31, 2024, Dr. Pace had not invoiced the Company for any consulting work under this agreement. In addition, to align the terms of stock option grants made to Dr. Pace prior to 2022 with those granted during or after 2022, the People & Compensation Committee approved a modification such that Dr. Pace’s then-vested stock options shall be exercisable for three years following the end of Dr. Pace’s service under his